فهرست نشریات علمی دسترسی آزاد ایران

Heart failure (HF) becomes multifaceted cardiovascular disease that affects the universal health burden. Treatments of mildly reduced ejection fraction heart failure (HFmrEF) as one of the HF categories are still in the grey area. This study aims to analyse the trends and bibliometric data, also to understand the HFmrEF therapy by content review. Bibliometric information was collected from Scopus Database. The bibliometric data were analysed using R-package bibliometrix and its web-interface biblioshiny was also visualized using VOSviewer. A total of 206 publications from 2016 to 2024 in heart failure therapy, HFmrEF was mostly discussed in 2023.  From the top 10 of global cited documents, only 3 documents discussed specifically about HFmrEF. Based on keyword analysis, HFmrEF were linked to HF therapies, including angiotensin receptor-neprilysin inhibitor (ARNi), angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), beta-blocker (BB), mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter-2 (SGLT2) inhibitor, which are the four pillars of reduced ejection fraction heart failure (HFrEF) therapy. There is an upward-stable trend of HF publications from 2016 to 2023, including those for HFmrEF which is the most discussed topic in 2023. In terms of HFmrEF therapy, the four pillars of HF therapy are related to HFmrEF based on visualization analysis, although those medications are currently recommended only for HFrEF. HFmrEF therapy is still an interesting issue for upcoming research due to limited established positive trials.